Authors
Latest:
KISIMA-01 Investigates the Safety of ATP128 With or Without Ezabenlimab in CRCScott Kopetz, MD, PhD, FACP, explains the purpose of the phase 1b KISIMA-01 study of the ATP128 vaccine used with or without with or without ezabenlimab to treat patients with advanced colorectal cancer.
Latest:
Updated Survival Data from BEACON CRC Lead to More Specific QuestionsScott Kopetz, MD, PhD, discusses the next steps following the phase 3 BEACON CRC trial of encorafenib plus cetuximab with or without binimetinib compared with irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E metastatic colorectal cancer.
Latest:
AP128 Vaccine Shows Preliminary Safety in Stage IV CRCScott Kopetz, MD, PhD, FACP, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.
Latest:
An Overview of the St. Jude Cloud Data-Sharing ResourceScott Newman, PhD, St. Jude Children’s Research Hospital, discusses the St. Jude Cloud data-sharing resource for the research community.
Latest:
Bevacizumab and Improvement of PFS in Ovarian CancerSean C. Dowdy, MD, professor, chair, Division of Gynecologic Surgery, co-leader, Women’s Cancer Program, Mayo Clinic, discusses bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.
Latest:
Idelalisib: A PI3K Inhibitor on the HorizonIdelalisib is a potent and highly selective PI3K inhibitor that promotes apoptosis in primary cells from patients with different B-cell malignancies. Idelalisib has been shown to affect microenvironmental signaling and cell survival both in vitro and in vivo.
Latest:
National Surge in Thyroid Cancer Under ScrutinyEach year approximately 63,000 persons in the US will be diagnosed with thyroid cancer, placing it among the top 10 most common cancers in the country.
Latest:
Risks and Benefits of Phase I Liver Dysfunction StudiesSelena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.
Latest:
A Trial Investigating CDK4/6 Inhibitors for the Treatment of Mantle Cell LymphomaSelina Chen-Kiang, PhD, a professor of pathology and immunology at Weill Cornell Medical College, discusses the rationale of her phase I trial investigating the use of CDK4/6 inhibitors for the treatment of patients with mantle cell lymphoma.
Latest:
Weight May Affect Toxicity of ImmunotherapiesImmunotherapy is the only alternative to chemotherapy and radiation for the treatment of advanced-stage tumors and recent research has shown a correlation between weight and the toxicity of these immunotherapies.
Latest:
Venetoclax in Combination with Daratumumab for Multiple Myeloma TreatmentSponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. A look at clinical trial efficacy data on daratumumab plus bortezomib and venetoclax for multiple myeloma treatment.
Latest:
Managing Infections During Bispecific Therapy for Multiple MyelomaShaji Kumar, MD, discusses the incidence and management of infections in patients receiving teclistamab-cqyv or other bispecific agents for relapsed/refractory multiple myeloma.
Latest:
Cristofanilli Reviews CDK 4/6 Inhibitors in the Case of a Patient With ER-Positive Breast CancerDuring a recent <em>Targeted Oncology </em>case-based peer perspectives live dinner event, Massimo Cristofanilli, MD, explained the options for treatment based on the case scenario of a woman with ER-positive breast cancer.<br />
Latest:
Results of the ENPAC Trial Shows Promise in Recurrent Endometroid CancerShannon N. Westin, MD, MPH, discusses the promising results of the ENPAC trial that showed the effectiveness of adding enzalutamide to standard of care chemotherapy for patients with recurrent endometriod cancer.
Latest:
Palbociclib Combined With Fulvestrant in Relapsed Metastatic HR+/HER2- Breast CancerShannon Puhalla, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses a phase III study examining the combination of palbociclib and fulvestrant for the treatment of patients with relapsed metastatic hormone receptor-positive, HER2-negative breast cancer.
Latest:
Westin Discusses Insights From the DUO-E Trial in Endometrial CancerShannon Westin, MD, MPH, FACOG, discusses her hopes following the presentation of promising data from the phase 3 DUO-E trial of durvalumab plus chemotherapy followed by durvalumab and olaparib maintenance in patients with newly diagnosed advanced or recurrent endometrial cancer.
Latest:
Recent Events Raise Awareness of BRCA TestingSharon Tollin, PhD, ARNP-BC, OCN®, H. Lee Moffitt Cancer Center & Research Institute, discusses changes to the awareness of BRCA testing and breast cancer risk.
Latest:
The Importance of BRCA Testing in Ovarian CancerSharyn N. Lewin, MD, discusses the importance of screening patients with ovarian cancer for a BRCA mutation.
Latest:
Synergy of Radiotherapy and Anti-PD-1 Therapy With Pembrolizumab in NSCLC: Is This Perfect Harmony?The investigators discuss their findings that demonstrate patients with previous radiotherapy experienced significantly longer PFS and OS with pembrolizumab treatment versus those with no previous radiotherapy.
Latest:
Dr. Sheri Holmen on Finding the Appropriate Treatments for Brain Metastases in MelanomaHolmen says that utilizing targeted therapies could potentially be the answer, though clinically-tested combinations have historically not done as well as clinicians had hoped.
Latest:
Avelumab Maintenance in Advanced Urothelial Carcinoma: Key InsightsShilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community oncologists.
Latest:
The Emerging Role of Checkpoint Inhibitors in Lymphoid MalignanciesIn this article, Shipra Gandhi, MD, Pallawi Torka, MD, and Francisco J. Hernandez Ilizaliturri, MD summarize the current clinical development of these novel agents in lymphoid malignancies.
Latest:
Gadgeel on MARIPOSA Trial Updates in EGFR+ NSCLCShirish M. Gadgeel, MD, provides and overview of the MARIPOSA trial of lazertinib and amivantamab vs osimertinib in EGFR-mutated advanced or metastatic NSCLC.
Latest:
Rethinking the Treatment of Aggressive Thyroid CancerShlomo Koyfman, MD, discusses registry data on thyroid cancer and how data from the registry can improve practice for oncologists.
Latest:
Clinical Pearls for Oncologists Treating Patients With BCG-Unresponsive NMIBCBCG-unresponsive NMIBC requires vigilant surveillance during new treatments to avoid missing signs of progression and avoid delaying cystectomy, which remains the best chance for cure if intravesical therapies are failing.
Latest:
The Potential for Implantable Cardiac Devices to Malfunction Following Radiation TherapySiavash Jabbari, MD, discusses the potential for implantable cardiac devices such as pacemakers to malfunction following radiation therapy.
Latest:
An Overview of the GeparSepto Trial in Luminal, Triple-Negative, and HER2+ Breast CancerSibylle Loibl, MD, PhD, co-chair of the German Breast Group and associate professor at the University of Frankfurt, discusses the most recent subanalysis of the GeparSepto trial in luminal, triple-negative, and HER2+ breast cancer.
Latest:
Treatment Sequencing Considerations for BRAF-Mutant MelanomaWith expanding availability of effective single-agent and combination immunotherapies and combination BRAF/MEK inhibitor regimens, all of which have been shown to improve survival and reduce risk of progression, the optimal sequencing of therapies has become increasingly complex.
Latest:
Combination Regimens for Metastatic MelanomaA number of new combination approaches have gained approval in the past year for the treatment of patients with BRAF-mutant metastatic melanoma, expanding the number of effective treatment options that can improve quality and length of life for many patients.
